1-2 of 2
Francesco Paolo D'Armiento
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cancer-Associated CD43 Glycoforms as Target of Immunotherapy

Free
Franca Maria Tuccillo, Camillo Palmieri, Giuseppe Fiume, Annamaria de Laurentiis, Marco Schiavone, Cristina Falcone, Enrico Iaccino, Ricciarda Galandrini, Cristina Capuano, Angela Santoni, Francesco Paolo D'Armiento, Claudio Arra, Antonio Barbieri, Fabrizio Dal Piaz, David Venzon, Patrizia Bonelli, Franco Maria Buonaguro, Iris Scala, Massimo Mallardo, Ileana Quinto, Giuseppe Scala
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (3): 752–762.
https://doi.org/10.1158/1535-7163.MCT-13-0651
Published: 09 March 2014
View articletitled, Cancer-Associated CD43 Glycoforms as Target of Immunotherapy
Open the PDF for Cancer-Associated CD43 Glycoforms as Target of Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model

Free
David Raben, Cataldo Bianco, Vincenzo Damiano, Roberto Bianco, Davide Melisi, Chiara Mignogna, Francesco Paolo D'Armiento, Luca Cionini, A. Raffaele Bianco, Giampaolo Tortora, Fortunato Ciardiello, Paul Bunn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (8): 977–983.
https://doi.org/10.1158/1535-7163.977.3.8
Published: 06 August 2004
View articletitled, Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model
Open the PDF for Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model in another window